New research into cancer “dark matter” reveals hidden cancer signals immune system can’t find, offering a fuller picture of why immunotherapy fails for many patients.
The Assumption That’s Costing Patients Answers
Most conversations about immunotherapy success or failure start in the same place: mutations. How many does the tumor have? Which checkpoints are blocked? What does the mutation burden look like? For patients who have already been through this analysis and still didn’t respond, this framing carries a quiet cruelty. It implies the answer should have been findable. A growing body of research suggests the real problem is that oncologists have been looking at the visible part of a much larger picture. The hidden cancer signals the immune system can’t find may be doing more work than anyone previously mapped.
What’s Actually at Stake
If that’s true, then the dominant explanation for immunotherapy failure — the one that has shaped treatment decisions for years — is incomplete in ways that matter for patients who have run out of standard options.
Wait. No em dashes. Let me restate.
If that’s true, then the dominant explanation for immunotherapy failure, the explanation that has shaped treatment decisions for years, is incomplete in ways that matter for patients who have run out of standard options. By the end of this post, you’ll have a clearer framework for what “dark matter” in cancer immunology actually means, why it may explain non-response better than known mutations alone, and what kinds of research tools are beginning to close that gap.
The Gap That Took Time to Name
Oncologists are not wrong to look at mutations and checkpoint pathways. Those mechanisms are real, validated across thousands of patients, and the therapies built around them have extended lives. The problem is not that this work was misguided. The problem is that it left a large fraction of tumor biology unmapped, and when patients didn’t respond, the incomplete map looked like a complete one. Researchers are now naming what was missing: a layer of biological activity they’re calling “dark matter.” Not because it’s mysterious in a vague sense. Because it simply wasn’t being measured.
What a Burned Piece of Toast Has to Do with Your Immune System
Imagine a building’s smoke detector that goes off not because of a real fire, but because someone burned toast. It still triggers the full emergency response: sprinklers, alarms, evacuation. Cancer cells producing these “dark matter” signals work in exactly that way, generating a false alarm the immune system treats as completely real.
In this mapping, the burned toast represents the abnormal molecules, including unusual proteins and double-stranded RNA, that cancer cells produce as byproducts of their chaotic internal activity. The smoke detector is the immune system’s pathogen-sensing machinery, which cannot distinguish a genuine viral threat from these impostor signals. Researchers are now using combined multiomics analysis to map exactly which tumors produce enough of these signals to set off the alarm, and which ones slip past it undetected. In the lab, this means layering data from genomics, proteomics, metabolomics, and other biological systems simultaneously to find patterns that no single lens could reveal.
The Mechanism, and Why the Numbers Matter
The specific biological process involved is called viral mimicry. Cancer cells generate internal molecular signals that resemble the byproducts of an active viral infection, which prompts the immune system to mount an immune-cell-death response against the tumor, a process called immunogenic cell death. This is not an incidental quirk. It is, according to this review, a central driver of whether a tumor becomes immunologically visible or effectively invisible. The factors shaping it include not just genetics but epigenetic dysregulation, non-canonical proteins that standard sequencing doesn’t capture, interactions with gut bacteria, and metabolic reprogramming inside the tumor microenvironment.
The scale of this is worth stating precisely. As the authors write: “The mechanisms inducing VM and ICD are conserved across different cancer types independent of their ontogeny and affect about 2/3 of neoplasms across indications.” That figure, approximately two-thirds of all cancers, means these hidden biological signals are not a niche subtype problem. This paper is a synthesis of existing research across multiple fields, not a clinical trial, and no survival data or patient response rates are presented. What it does is lay out a framework for what the field now needs to measure, and why measuring it could change how non-response is understood and eventually addressed.
TAM’s Role in This Research
TAM’s Chief Scientific Officer, Francesco Marincola, is a co-author on this review. His participation reflects TAM’s focus on translational frameworks that connect biological mechanisms to patient-level questions about treatment response, and situates this research within the center’s broader interest in multiomics approaches to cancer immunology.
Where This Points Next
This review does not offer a treatment. What it offers is a more complete set of questions. In translational medicine, that’s often what changes the direction of a field.
The next step the research points toward is using multiomics tools, including AI-based integration of these layered data types, to identify which patients carry tumors with high viral mimicry activity, which carry tumors that suppress it, and how those differences can be targeted therapeutically. That work is investigational. The timelines are real, not certain. But the identification of a mechanism this broadly conserved, across approximately two-thirds of cancer types, gives researchers a target that wasn’t precisely named before.
If You Want to Understand Your Own Non-Response
Ask your care team whether your tumor has been evaluated for anything beyond mutation burden and checkpoint expression. The more precisely your tumor’s biology is mapped, the more precisely the right next question can be asked.
Source
De Rosis S; Monaco G; Hu J; Hett E; Lappano R; Marincola FM; Asadi A; Maggiolini M. “The dark matter in cancer immunology: beyond the visible, unveiling multiomics pathways to breakthrough therapies.” Journal of Translational Medicine 2025;23(1):808. doi:10.1186/s12967-025-06839-y. https://doi.org/10.1186/s12967-025-06839-y
Read the full study
Source
De Rosis S; Monaco G; Hu J; Hett E; Lappano R; Marincola FM; Asadi A; Maggiolini M. “The dark matter in cancer immunology: beyond the visible– unveiling multiomics pathways to breakthrough therapies.” Journal of Translational Medicine 2025;23(1):808. doi:10.1186/s12967-025-06839-y. https://doi.org/10.1186/s12967-025-06839-y
Frequently Asked Questions
Cancer cells can produce abnormal molecules, including unusual proteins and double-stranded RNA, that resemble the byproducts of a viral infection happening inside the cell. The immune system detects these signals and treats the tumor the way it would treat an infected cell, mounting an attack against it. Researchers believe understanding this mechanism could help explain why some tumors are targeted by the immune system while others are not.
These signals span multiple biological layers, including gene activity, proteins, metabolites, gut bacteria, and epigenetic changes, and no single test captures all of them at once. The study describes how combining several data types through multi-omics analysis is what makes these hidden signals visible. A standard biopsy or blood test looks at only one layer at a time and would miss most of this picture.
This is a review paper, meaning the authors synthesized existing research across genomics, epigenetics, proteomics, metabolomics, microbiomics, and AI-based analysis rather than conducting a new clinical trial. The paper maps the biological mechanisms behind viral mimicry and immune rejection in cancer and finds these mechanisms appear to be conserved across roughly two-thirds of all cancer types. The core argument is that integrating multiple data types is necessary to understand why some tumors respond to immunotherapy and others do not.
It suggests the viral mimicry and immune rejection signals described in this paper are not specific to one cancer type but are a broad feature of how tumors behave across many different indications. That breadth means research findings and analytical tools built around these signals could potentially apply across a wide range of cancers rather than only one or two. At this stage, this is a research-level observation, not a clinical finding.
The paper points in that direction, identifying a wide range of hidden biological factors, from gut bacteria to gene regulation to obscure proteins, that may contribute to treatment failure. The idea is that tumors can evade the immune response by suppressing or disguising these viral mimicry signals, but that mapping them through multi-omics could reveal where the breakdown occurs. These are investigational directions for future research, not confirmed explanations based on clinical trial data.
Yes. Francesco Marincola, a researcher at TAM Center, is a co-author on this paper. His involvement reflects TAM Center’s focus on translating molecular and immunological research into frameworks that can inform future cancer therapy development.
No treatment is available from this research. This paper is a review that synthesizes existing scientific literature and identifies directions for future investigation. No clinical trials, therapies, or patient programs stem directly from this publication at this time.
Interested in what targeted diagnostics could reveal about your own biology? Start with a conversation with the TAM Center team.
Schedule a Consultation